CTC Bio, Inc.

Quick facts

Phase 3 pipeline

• CDFR0612 · Diabetes
  CDFR0612 is a small molecule that targets the SGLT2 receptor.
• CDFR0613 · Diabetes
  CDFR0613 is a small molecule that targets the SGLT2 receptor.

Phase 2 pipeline

• Condencia · Other

Phase 1 pipeline

• CDFF0318, Champix

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• CTC Bio, Inc. portfolio CI brief
• CTC Bio, Inc. pipeline updates RSS